title: Pharmacokinetic fate of 14C-labelled fumonisin B1 in swine.
abstract: The pharmacokinetics of the mycotoxin fumonisn B1 (FB1) were investigated in pigs. Animals were administered 14C-FB1 intravenously (IV; 0.25 microCi, 0.40 mg/kg) or intragastrically (IG; 0.35 microCi, 0.50 mg/kg); separate groups of pigs underwent bile cannulation prior to dosing (groups IV/B and IG/B, respectively). Blood, urine, faeces, (and bile), were collected at specific time intervals over 72 hr, and assayed for specific activity. Following IV dosing, plasma concentration-time profiles were triexponential, with the following mean values: t1/2 alpha, 2.2 min; t1/2 beta, 10.5 min; t1/2 gamma, 182 min; apparent volume distribution (Vd gamma), 2.4 l kg-1; plasma clearance, 9.1 ml min-1 kg-1. After 3 days, clearance of FB1-derived radioactivity from the body had slowed to trace levels; total recoveries in urine and faeces were 21.2% and 58.3%, respectively. In bile-interrupted pigs (IV/B) the absence of the slow terminal elimination phase (gamma) suggested FB1 underwent enterohepatic circulation. Biliary recovery was 70.8% of the IV-dose. Radioactivity remaining in tissues after 72 hr amounted to 19.8% and 11.9% of the dose given to IV and IV/B pigs, respectively; highest activities were measured in liver and kidney equivalent to 1,076 and 486 ng FB1 and/or metabolites per g tissue, respectively. Based on plasma and excretion data, systemic bioavailability following IG dosing was estimated to be a very limited 3-6%. Tissue residue levels following IG dosing were 10-20-fold less than IV dosing.
authors.affiliation: Centre for Food and Animal Research, Agriculture Canada, Central Experimental Farm, Ottawa.
authors.forename: D B
authors.initials: DB
authors.lastname: Prelusky
authors.forename: H L
authors.initials: HL
authors.lastname: Trenholm
authors.forename: M E
authors.initials: ME
authors.lastname: Savard
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002274:Carcinogens, Environmental / Q000009:adverse effects / Q000493:pharmacokinetics*; D037341:Fumonisins; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D009183:Mycotoxins / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D013552:Swine / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D002274:Carcinogens, Environmental; D037341:Fumonisins; D009183:Mycotoxins; C056933:fumonisin B1